Achaogen’s Fight in Antibiotic Space Highlighted in Article
BayBio member Achaogen was recognized in an August 14 article of Genetic Engineering & Biotechnology News.
Author Gail Dutton reports in Biopharmas Drive Antibiotic Development that more effective targets are needed to deal with rising antibiotic resistance.
According to the article, Achaogen is focused on multi-drug-resistant, gram-negative. In April, it was awarded a $60 million contract from the Biomedical Advanced Research and Development Authority (BARDA). The funds will be used to conduct a global Phase III study to evaluate the safety and efficacy of plazomicin for patients with gram-negative bacterial infections caused by carbapenem-resistant Enterobacteriaceae (CRE). The study is scheduled to begin during the fourth quarter of 2013. Plazomicin (ACHN-490) is a next-generation neoglycoside that has demonstrated efficacy against many pathogens.
Achaogen is one of 66 companies involved in antibiotics research and 86 percent were small to medium sized organizations, according to the article.